<li>atazanavir<p>atazanavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>boceprevir<p>boceprevir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Potential for myopathy, including rhabdomyolysis.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>clarithromycin will increase the level or effect of simvastatin by  Other (see comment). Contraindicated. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>cobicistat<p>cobicistat will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious reactions such as myopathy including rhabdomyolysis</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated.  Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.<span><br><br></span>cyclosporine will increase the level or effect of simvastatin by  Other (see comment). Contraindicated. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>danazol<p>danazol increases toxicity of simvastatin by decreasing metabolism. Contraindicated. Contraindicated.  Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.</p></li><li>darunavir<p>darunavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>delavirdine<p>delavirdine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>erythromycin ethylsuccinate increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>erythromycin lactobionate increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>erythromycin stearate increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>gemfibrozil<p>gemfibrozil, simvastatin.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Contraindicated with other lipid-lowering drugs that can cause myopathy.<span><br><br></span>gemfibrozil will increase the level or effect of simvastatin by  Other (see comment). Contraindicated. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>idelalisib<p>idelalisib will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis</p></li><li>indinavir<p>indinavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.<span><br><br></span>simvastatin will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Contraindicated.<span><br><br></span>indinavir increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>ketoconazole increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>lopinavir<p>lopinavir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.</p></li><li>mifepristone<p>mifepristone increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated due to increased risk of rhabdomyolysis.<span><br><br></span>mifepristone increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.<span><br><br></span>simvastatin will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Contraindicated.<span><br><br></span>nelfinavir increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk of myopathy, including rhabdomyolysis.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk of myopathy, including rhabdomyolysis<span><br><br></span>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>posaconazole will increase the level or effect of simvastatin by  P-glycoprotein (MDR1) efflux transporter. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure</p></li><li>red yeast rice<p>simvastatin, red yeast rice.
Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. May increase creatine kinase levels and increase risk of myopathy or rhabdomyolysis; red yeast rice contains monocolin K (reportedly identical to lovastatin).</p></li><li>ritonavir<p>ritonavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.<span><br><br></span>simvastatin will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Contraindicated.<span><br><br></span>ritonavir increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>saquinavir<p>simvastatin will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Contraindicated.<span><br><br></span>saquinavir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.<span><br><br></span>saquinavir increases toxicity of simvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>telaprevir<p>telaprevir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Potential for myopathy including rhabdomyolysis.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simstatin systemic exposure<span><br><br></span>simvastatin will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure<span><br><br></span>telithromycin will increase the level or effect of simvastatin by  Other (see comment). Contraindicated. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>tipranavir<p>tipranavir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis.</p></li>